Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03313778




Registration number
NCT03313778
Ethics application status
Date submitted
13/10/2017
Date registered
18/10/2017
Date last updated
4/06/2024

Titles & IDs
Public title
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Scientific title
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Secondary ID [1] 0 0
2023-505192-77-00
Secondary ID [2] 0 0
mRNA-4157-P101
Universal Trial Number (UTN)
Trial acronym
KEYNOTE-603
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - mRNA-4157
Other interventions - Pembrolizumab
Other interventions - SoC Treatment

Experimental: Part A: Dose Escalation and Dose Expansion - Participants will receive mRNA-4157 via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.

Experimental: Part B: Dose Escalation and Dose Expansion - Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.

Experimental: Part A2: Dose Expansion - Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle and a SoC treatment every 2 weeks (Q2W) on Day 1 of each 21-day cycle starting from Cycle 5 of mRNA-4157 for up to 12 cycles.

Experimental: Part C: Dose Expansion - Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.

Experimental: Part D: Dose Expansion - Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 18 cycles (approximately 1 year of treatment), whichever is sooner.

Experimental: Part E1: Dose Expansion - Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab every 6 weeks (Q6W) via IV infusion, and SoC chemotherapy every 3 weeks (Q3W) for up to 4 cycles during the perioperative and adjuvant phases.

Experimental: Part E2: Dose Expansion - Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q6W via IV infusion, and SoC chemotherapy Q3W for up to 4 cycles during the perioperative and adjuvant phases.

Experimental: Part E3: Dose Expansion - Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q3W via IV infusion, and SoC chemotherapy Q2W or Q3W for up to 4 cycles during the perioperative and adjuvant phases.


Other interventions: mRNA-4157
IM injection

Other interventions: Pembrolizumab
Intravenous infusion

Other interventions: SoC Treatment
Intravenous infusion
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Adverse Events
Timepoint [1] 0 0
Part A and A2: Baseline through 100 days after last mRNA-4157 dose; Parts B, C, D, E1, E2, and E3: Baseline through 90 days after last pembrolizumab dose
Secondary outcome [1] 0 0
Part C: Overall Response Rate (ORR): Number of Participants with Tumor Response (Partial or Complete)
Timepoint [1] 0 0
Baseline through disease progression by Response Evaluation Criteria of Solid Tumors Version 1.1 (RECIST 1.1), start of new anti-cancer therapy, withdrawal of consent, death and last safety follow-up visit (up to approximately 3 years)
Secondary outcome [2] 0 0
Part C: Duration of Response (DoR)
Timepoint [2] 0 0
Baseline through disease progression by RECIST 1.1, start of new anti-cancer therapy, withdrawal of consent, death and last safety follow-up visit (up to approximately 3 years)
Secondary outcome [3] 0 0
Part C: Progression Free Survival (PFS)
Timepoint [3] 0 0
Baseline through disease progression by RECIST 1.1, start of new anti-cancer therapy, withdrawal of consent, death and last safety follow-up visit (up to approximately 3 years)
Secondary outcome [4] 0 0
Part C: Overall Survival (OS)
Timepoint [4] 0 0
Baseline to death of any cause (up to approximately 3 years)
Secondary outcome [5] 0 0
Part A2: Recurrence-free Survival (RFS)
Timepoint [5] 0 0
Baseline up to 2 years
Secondary outcome [6] 0 0
Parts A2, E1, E2, and E3: Number of Participants with Presence or Absence of Circulating Tumor DNA (ctDNA)
Timepoint [6] 0 0
Baseline up to 2 years
Secondary outcome [7] 0 0
Parts E1 and E2: Event-free Survival (EFS)
Timepoint [7] 0 0
Baseline up to 2 years
Secondary outcome [8] 0 0
Part E3: EFS
Timepoint [8] 0 0
Baseline up to 2 years

Eligibility
Key inclusion criteria
- Parts A, A2, and D: Participants must be clinically disease-free at study entry (that
is, participants in the adjuvant setting).

- Part B: Participants must have one of the histologically- or cytologically-confirmed
unresectable (locally advanced or metastatic) protocol-specified solid malignancies,
have measurable disease at study entry defined by RECIST 1.1., and be considered
suitable for treatment with pembrolizumab; in this study pembrolizumab will be
considered an investigational study drug.

- Part C: Participants must have one of the histologically- or cytologically confirmed
unresectable (locally advanced or metastatic) protocol-specified solid malignancies,
must not have received prior anti-programmed cell death protein 1 (PD-1)/programmed
death -ligand 1 (PD-L1) therapy, and must have measurable disease at study entry
defined by RECIST 1.1.

- Part A2: Participants with histologically confirmed PDAC who have undergone complete
macroscopic resection(that is, R0 - no cancer cells within 1 mm of all resection
margins or R1 - cancer cells present within 1 mm of one or more resection margins) who
had no evidence of metastatic disease with adequate recovery from surgery to receive
adjuvant therapy.

- Parts E1 and E2: Participants with untreated histologically/cytologically confirmed
Stage II-IIIB NSCLC (per AJCC version 8) that is considered resectable of non-squamous
(adenocarcinoma only) or squamous cell carcinoma histology, absence of major
associated pathologies that increase the surgery risk to an unacceptable level, must
have a tumor tissue sample available for NGS and PD-L1 IHC testing as defined in the
Laboratory Manual.

- Part E3: Participants with untreated, locally advanced surgically resectable,
histologically/cytologically confirmed, gastric/GEJ adenocarcinoma, as defined by a
primary lesion that is T3 or greater or with the presence of any positive clinical
nodes (N+) and without evidence of metastatic disease, measurable disease according to
RECIST version 1.1, absence of major associated pathologies that increase the surgery
risk to an unacceptable level, must have a tumor tissue sample available for NGS and
PD-L1 IHC testing as defined in the Laboratory Manual.

- Part D: Participants with completely resected Stage II, III or IV cutaneous melanoma.

- Parts A, A2, and D: Participants must have a formalin-fixed paraffin embedded (FFPE)
tumor sample available (for example, from their prior surgery) that is suitable for
the next generation sequencing (NGS) required for this study.

- Parts B and C: Participants must have at least 1 lesion amenable to the mandatory
fresh tumor biopsy at study entry.

- Participants must have resolution of toxic effect(s) (as specified in the protocol)
from prior therapy to Grade 1 or less.

- Participant is willing to use an adequate method of contraception for the course of
the study through 120 days after the last dose of study drug (male and female
participants of childbearing potential), or for a specified time after the last dose
of SoC chemotherapy per SoC product labeling, whichever is later.

- Participants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology
Group (ECOG) PS.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Treatment with any of the following:

1. Any investigational agents, anti-cancer monoclonal antibody, anti-cancer
therapeutic vaccine, immunostimulant (for example, IL-2), or study drugs from a
previous clinical study within 4 weeks of the first dose of mRNA-4157 or
pembrolizumab (note only a 2 week wash out is required from prior pembrolizumab
treatment)

2. Any chemotherapy, targeted small molecule therapy, or radiation therapy within 2
weeks of the first dose of mRNA-4157 or pembrolizumab

3. Live-virus vaccination within 30 days of the first dose of mRNA-4157 or
pembrolizumab. Seasonal flu vaccines that do not contain live virus are
permitted.

4. Any systemic steroid therapy or other form of immunosuppressive therapy within 7
days of the first dose of mRNA-4157 or pembrolizumab

5. Transfusion of blood products (including platelets or red blood cells [RBCs]) or
administration of colony stimulating factors (including granulocyte colony
stimulating factor [G-CSF], granulocyte/macrophage colony stimulating factor
[GM-CSF], or recombinant erythropoietin) within 1 week of the NGS blood sample
during screening, and 4 weeks of the first dose of mRNA-4157 or pembrolizumab

- A history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with participation for the
full duration of the study, or is not in the best interest of the participant to
participate, in the opinion of the treating Investigator

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial

- Previously identified hypersensitivity to components of the formulations used in this
study

- Known additional malignancy that is progressing or requires active treatment,
exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
skin that has undergone curative therapy, or in situ cervical cancer.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/08/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/06/2025
Actual
Sample size
Target
242
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
St Vincents Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Westmead Hospital-Cnr Hawkesbury and Darcy Road - Westmead
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
New Jersey
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ModernaTX, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of
mRNA-4157 alone and in combination in participants with solid tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03313778
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Moderna Clinical Trials Support Center
Address 0 0
Country 0 0
Phone 0 0
1-877-777-7187
Fax 0 0
Email 0 0
clinicaltrials@modernatx.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03313778